Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood … – Markets Insider
|
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood …
Markets Insider LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively … |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
Markets Insider … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
Markets Insider … delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. |
|
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood …
Markets Insider LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively … |
Ovarian Cancer News Today |
UC San Diego Team Receives $5.8 Million to Develop Immunotherapy for Ovarian, Other Cancer Patients
Ovarian Cancer News Today Researchers at the University of California San Diego School of Medicine have received a $5.8 million state grant to develop an immunotherapy against hard-to-kill cancer stem cells. The team that won the 30-month grant from the California Institute for … Award-winning Israeli cancer researcher says immunotherapy is the ‘future’ of treatmentJNS.org |
FierceBiotech |
Agilis forms joint venture to advance gene therapy vectors
FierceBiotech Agilis Biotherapeutics has formed a joint venture with Japan’s Gene Therapy Research Institution (GTRI). The alliance gives Agilis a base in Japan and a partnership with a fellow CNS specialist to support its development of adeno-associated virus (AAV) … Agilis Biotherapeutics and Gene Therapy Research Institution Enter into Strategic PartnershipBusiness Wire (press release) |